Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes

Published:2016-06-23 Issue:11 Volume:61 Page:923-929
ISSN:1434-5161
Container-title:Journal of Human Genetics
language:en
Short-container-title:J Hum Genet

Author:

Kim Ja Hye,Lee Beom Hee,Hyang Cho Ja,Kang Eungu,Choi Jin-Ho,Kim Gu-Hwan,Yoo Han-Wook

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Genetics

Link

http://www.nature.com/articles/jhg201678.pdf

Reference25 articles.

1. Germain, D. P. Fabry disease. Orphanet J. Rare Dis. 5, 30 (2010).

2. Askari, H., Kaneski, C. R., Semino-Mora, C., Desai, P., Ang, A., Kleiner, D. E. et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 451, 823–834 (2007).

3. Schiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S. et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 24, 2102–2111 (2009).

4. Mehta, A., Ricci, R., Widmer, U., Dehout, F., Garcia de Lorenzo, A., Kampmann, C. et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 34, 236–242 (2004).

5. Thurberg, B. L. & Politei, J. M. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. Hum. Pathol. 43, 610–614 (2012).

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry disease: development and progression of left ventricular hypertrophy despite long-term enzyme replacement therapy;Heart;2024-05-15

2. Inflammation and Exosomes in Fabry Disease Pathogenesis;Cells;2024-04-09

3. Outcomes and management of kidney transplant recipients with Fabry disease: a review;Journal of Nephrology;2024-01-16

4. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study;Orphanet Journal of Rare Diseases;2023-10-21

5. Treatment of Fabry Nephropathy: A Literature Review;Medicina;2023-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3